Compass Therapeutics Inc. Company Profile
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics at a glance
Compass Therapeutics Inc. (NASDAQ: CMPX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Compass Therapeutics is led by Dr. Thomas J. Schuetz M.D., Ph.D. and employs about 39 people. At a market capitalization of $122.2 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001738021, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Compass Therapeutics do?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Compass Therapeutics Inc.
- Ticker
- NASDAQ: CMPX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Thomas J. Schuetz M.D., Ph.D.
- Employees
- 39
- Headquarters
- 80 Guest Street, Boston, MA, United States
- Phone
- 617 500 8099
- Website
- compasstherapeutics.com
- Market cap
- $122.19M
- SEC CIK
- 0001738021
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to Compass Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs CMPX |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs CMPX |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs CMPX |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs CMPX |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs CMPX |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs CMPX |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs CMPX |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs CMPX |